ICTUS 2/3

ICTUS 2/3The purpose of this research study is to find out if the combination of dissolving blood clots using t-PA , a clot dissolving drug and hypothermia (lowering of body temperature) is better than dissolving blood clots alone for the treatment of stroke. The investigational hypothermia machine uses a special cooling catheter which is a flexible plastic and metal tube with is slightly smaller than a pencil, to cool and rewarm the body from the inside. This study is open to patients age 22 to 82, who have received t-PA using standard guidelines and can begin cooling within 2 hours of t-PA finishing. Patients will be followed for 3 months. This study is sponsored by National Institute of Neurological Disorders and Stroke and ZOLL Circulation, Inc.


iDEF

iDEFiDEF Is a clinical trial to look at the effects of the study drug Deferoxamine on a brain hemorrhage. This drug removes iron, and we are studying whether removal of iron from the brain after a brain hemorrhage will reduce the effects of the brain hemorrhage. We are also conducting this study to learn more about the safety of the drug. This study is open to patients 18 to 80, who have been diagnosed with a brain hemorrhage and where the drug can begin infusing within 24 hours of brain hemorrhage symptom onset. Patients will be followed for 6 months. This study is sponsored by The National Institute of Neurological Disorders and Stroke.


PROSPER

PROSPERThe goal of this study is to improve our understanding of current outpatient treatment patterns, as well as the use of medications and programs that are predicted to lower you risk of complications. By collecting information about participants, including; how they are doing, medical history, and treatments, researchers can try to understand what doctor’s do that allows patients to have the best possible outcome. Telephone interviews with patient’s ≥18 years old that have had a primary diagnosis of acute ischemic stroke are done at 3 and 6 months after discharge. The Duke Clinical Research Institute is conducting this study. This trial is currently enrolling.


SWIFT PRIME

CovidienThe purpose of this study is to compare two different ways of treating patients who have suffered a large stroke to find out which way might give patients a better outcome. This study will compare a group treated with IV t-PA ,a clot-dissolving drug through a vein, to a group that will be treated with a combination of IV t-PA and the SOLITARE™FR Device (FDA approved device to remove a blood clot and to restore blood flow to the brain) to find out which treatment is better at improving stroke-related symptoms with fewer side effects. Patients will be followed for 90 days. This study is sponsored by Covidien LP. This study is on hold currently for data analysis and is anticipated to resume enrollment in early 2015.


MISTIE III

MISTIE IIIThis research is being done to evaluate the recovery of participants who receive a study drug called rt-PA (recombinant tissue plasminogen activator) when used with minimal invasive surgery for the removal of a blood clot from the brain. These patients are compared to participants who receive standard medical care meaning no surgery and no study drug. This study is open to patients age 18 to 80, who have a diagnosis of sudden bleeding in the brain, and who meet other medical criteria. Patients in the study will be followed for 12 months. This study is sponsored by the National Institute of Neurological Disorders and Johns Hopkins University.


RESPECT ESUS

BoehringerThis research is being done to compare the safety and efficacy of the drug dibigatran etexilate versus aspirin in patients with a condition called embolic stroke of undetermined source, a type of stroke when an artery supplying the blood to the brain becomes blocked and the origin of the blood clot is not identifiable. This study is open to patient’s ≥60 years old with an ischemic stroke of undetermined source up to 3 months or 6 in certain circumstances, prior to enrolling and who meet other medical criteria. Patients in the study will be followed for up to 3 years. This study is being sponsored by Boehringer Ingelheim. This trial is anticipated to begin enrollment in early 2015.


SOCRATES

AstraZenecaThis research is being carried out to compare the effect of the new drug ticagrelor given twice daily compared to aspirin given once daily for the prevention of death, heart attack and stroke in patients with acute ischemic stroke or transient ischemic attach (TIA). This study is open to patients 40 years old and older who have suffered from an acute ischemic attack or a high risk TIA. Patients will be followed for 4 months, involving a total of 6 visits. This study is being sponsored by AstraZeneca and is anticipated to begin enrollment in the spring of 2015.